Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers
about
Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv miceA single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimatVirus maturation as a new HIV-1 therapeutic targetPhase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infectionPharmacological intervention of HIV-1 maturationRole of Marine Natural Products in the Genesis of Antiviral AgentsNine crystal structures determine the substrate envelope of the MDR HIV-1 proteaseVirtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid.Drug interactions with new and investigational antiretrovirals.Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitorsPolymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimatA historical overview of natural products in drug discovery.Conjugates of betulin derivatives with AZT as potent anti-HIV agents.HIV entry inhibitors and their potential in HIV therapyBevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.New betulinic acid derivatives as potent proteasome inhibitorsAnti-AIDS agents 88. Anti-HIV conjugates of betulin and betulinic acid with AZT prepared via click chemistryAnti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors.Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457)Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agentsNovel compounds for the treatment of HIV type-1 infection.New approaches for antiviral targeting of HIV assembly.Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1.Estrogen Receptor Signaling and the PI3K/Akt Pathway Are Involved in Betulinic Acid-Induced eNOS Activation.An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat.Emerging antiviral drugs
P2860
Q21092230-73E42332-1D11-4B2C-8542-EF97EA342065Q24606079-5945803A-DBA1-46A7-8A0E-C6C0415825D5Q24642446-21910FAE-91B1-4B1E-856C-F94C318050B9Q24672964-EF5EA606-AB6A-4CBA-A3E8-7BF6D9E0CEDFQ26771739-FB4763D0-767E-4251-8EB5-960387EA4AECQ26796360-49324E9B-7DE9-4A7D-89F7-6334F9007651Q27666929-EC61D367-40D6-415C-961A-F4AA071E8095Q33774977-3E861EDC-35E0-4213-BEAC-BA8DC6F264A9Q33801821-5F2BD12B-9528-48C1-AEF8-373DC24CE27EQ33814879-50532D1F-B5CD-401B-98B0-B2EBB9D5C2E1Q33864444-EC57B5EA-2E95-4985-A899-A63B4E07245BQ34426191-113DD451-9FB8-4185-93C5-79AFA913B598Q34468057-7E0A3E54-6F65-4517-AD55-E6C176E88ED6Q34595921-728DBF81-EF97-4F08-BD20-4790F0EBD8BCQ34885660-51DFC0C3-91C9-4B6D-A238-CE41A4651612Q35209514-0EF239D6-37DA-4DBA-BFDD-25E8F276135EQ36034205-4AF62FDD-6B0E-458E-905E-6FBE716F1C70Q36340098-93104584-5D68-468B-84F1-F39D73B8E1FAQ37192174-265092F7-3B5E-43FF-9F03-A053ADC126EAQ37330178-679215A5-30A5-453F-B4E7-35216B22C665Q37502492-FCC10B45-3787-46F6-91D1-04975D1F61FAQ37901613-7A266B58-8F8A-465C-8197-98C57536EFB5Q38743504-98B524DC-25E2-4BEB-8383-9FAB863B6775Q38755380-AD7F261D-ED47-48A4-911A-0153C0E032C9Q46079242-99952FC6-7EA6-408C-84F5-4219DBCD3E17Q56786308-43E7E4BA-2A54-4335-84D5-3DFC2939E7BC
P2860
Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Safety and pharmacokinetics of ...... uration, in healthy volunteers
@ast
Safety and pharmacokinetics of ...... uration, in healthy volunteers
@en
Safety and pharmacokinetics of ...... uration, in healthy volunteers
@nl
type
label
Safety and pharmacokinetics of ...... uration, in healthy volunteers
@ast
Safety and pharmacokinetics of ...... uration, in healthy volunteers
@en
Safety and pharmacokinetics of ...... uration, in healthy volunteers
@nl
prefLabel
Safety and pharmacokinetics of ...... uration, in healthy volunteers
@ast
Safety and pharmacokinetics of ...... uration, in healthy volunteers
@en
Safety and pharmacokinetics of ...... uration, in healthy volunteers
@nl
P2093
P2860
P356
P1476
Safety and pharmacokinetics of ...... uration, in healthy volunteers
@en
P2093
Charles Ballow
David E Martin
Gina L Burgess
Hal Galbraith
John Wilton
Philip C Smith
Robert Blum
P2860
P304
P356
10.1128/AAC.01391-06
P407
P577
2007-09-01T00:00:00Z